Hypothesis: upfront use of ABL kinase inhibitor combination, either simultaneously or sequentially, in high-risk Ph+ leukemias?
Carella, A M
Hypothesis: upfront use of ABL kinase inhibitor combination, either simultaneously or sequentially, in high-risk Ph+ leukemias? [electronic resource] - Annals of hematology Jun 2010 - 531-3 p. digital
Publication Type: Journal Article; Review
1432-0584
10.1007/s00277-010-0907-3 doi
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Drug Administration Schedule
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy
Models, Theoretical
Neoadjuvant Therapy
Protein Kinase Inhibitors--administration & dosage
Proto-Oncogene Proteins c-abl--antagonists & inhibitors
Risk Factors
Hypothesis: upfront use of ABL kinase inhibitor combination, either simultaneously or sequentially, in high-risk Ph+ leukemias? [electronic resource] - Annals of hematology Jun 2010 - 531-3 p. digital
Publication Type: Journal Article; Review
1432-0584
10.1007/s00277-010-0907-3 doi
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Drug Administration Schedule
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy
Models, Theoretical
Neoadjuvant Therapy
Protein Kinase Inhibitors--administration & dosage
Proto-Oncogene Proteins c-abl--antagonists & inhibitors
Risk Factors